These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 1796912

  • 1. Comparative pharmacokinetics and distribution of human urinary erythropoietin and recombinant human erythropoietin in rats.
    Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A.
    Arzneimittelforschung; 1991 Sep; 41(9):1004-7. PubMed ID: 1796912
    [Abstract] [Full Text] [Related]

  • 2. Distribution of recombinant human erythropoietin following multiple intravenous administration and effects of age on the distribution in rats.
    Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A.
    Arzneimittelforschung; 1992 Apr; 42(4):579-84. PubMed ID: 1642686
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and distribution of recombinant erythropoietin in rats.
    Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A.
    Arzneimittelforschung; 1992 Feb; 42(2):174-8. PubMed ID: 1610430
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and distribution of recombinant human erythropoietin in rats with renal dysfunction.
    Kinoshita H, Ohishi N, Tokura S, Okazaki A.
    Arzneimittelforschung; 1992 May; 42(5):682-6. PubMed ID: 1530684
    [Abstract] [Full Text] [Related]

  • 5. Preparation of iodine labeled recombinant human erythropoietin.
    Kinoshita H, Ohishi N, Okazaki A.
    Arzneimittelforschung; 1991 May; 41(5):568-70. PubMed ID: 1898429
    [Abstract] [Full Text] [Related]

  • 6. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats.
    Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.
    J Pharmacol Exp Ther; 1997 Nov; 283(2):520-7. PubMed ID: 9353365
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of erythropoietin in genetically anemic mice.
    Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.
    Drug Metab Dispos; 1998 Feb; 26(2):126-31. PubMed ID: 9456298
    [Abstract] [Full Text] [Related]

  • 8. In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep.
    Widness JA, Veng-Pedersen P, Schmidt RL, Lowe LS, Kisthard JA, Peters C.
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1205-10. PubMed ID: 8968342
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats.
    Yoon WH, Park SJ, Kim IC, Lee MG.
    Res Commun Mol Pathol Pharmacol; 1997 May; 96(2):227-40. PubMed ID: 9226757
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in rats.
    Kato M, Okano K, Sakamoto Y, Miura K, Uchimura T, Saito K.
    Arzneimittelforschung; 2001 Jan; 51(1):91-5. PubMed ID: 11215332
    [Abstract] [Full Text] [Related]

  • 11. Biological characterization of recombinant human erythropoietin.
    Krumwieh D, Arnold I, Seiler FR.
    Behring Inst Mitt; 1988 Aug; (83):193-201. PubMed ID: 3240225
    [Abstract] [Full Text] [Related]

  • 12. Immunological response to repeated administration of recombinant human erythropoietin in rats: biphasic effect on its pharmacokinetics.
    Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.
    Drug Metab Dispos; 1997 Sep; 25(9):1039-44. PubMed ID: 9311618
    [Abstract] [Full Text] [Related]

  • 13. Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin.
    Misaizu T, Matsuki S, Strickland TW, Takeuchi M, Kobata A, Takasaki S.
    Blood; 1995 Dec 01; 86(11):4097-104. PubMed ID: 7492766
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of erythropoietin in intact and anephric dogs.
    Fu JS, Lertora JJ, Brookins J, Rice JC, Fisher JW.
    J Lab Clin Med; 1988 Jun 01; 111(6):669-76. PubMed ID: 3373111
    [Abstract] [Full Text] [Related]

  • 15. Binding of iodinated erythropoietin to rat bone marrow cells under normal and anemic conditions.
    Akahane K, Tojo A, Fukamachi H, Kitamura T, Saito T, Urabe A, Takaku F.
    Exp Hematol; 1989 Feb 01; 17(2):177-82. PubMed ID: 2536329
    [Abstract] [Full Text] [Related]

  • 16. Responsiveness to recombinant human erythropoietin (rh-Epo) of marrow erythroid progenitors (CFU-E and BFU-E) from B-chronic lymphocytic leukemia (B-CLL).
    Tsatalas C, Chalkia P, Tsantali C, Kakoulidis I, Garyfallos A, Klonizakis I, Panayiotopoulos S.
    J Exp Clin Cancer Res; 1997 Jun 01; 16(2):163-70. PubMed ID: 9261742
    [Abstract] [Full Text] [Related]

  • 17. Optimal erythroid cell production during erythropoietin treatment of mice occurs by exploiting the splenic microenvironment.
    Nijhof W, Goris H, Dontje B, Dresz J, Loeffler M.
    Exp Hematol; 1993 Apr 01; 21(4):496-501. PubMed ID: 8462658
    [Abstract] [Full Text] [Related]

  • 18. Comparative tissue distribution of 125I- and U-14C-labeled recombinant human interleukin-2 in the rat.
    Sabo J, Ni G, Nadeau R, Liberato DJ, Loh A.
    Lymphokine Cytokine Res; 1992 Aug 01; 11(4):229-33. PubMed ID: 1420601
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of human activated protein C. 2nd communication: tissue distribution study of a lyophilized purified human activated protein C after single or repeated intravenous administration in male mice and placental transfer and milk passage study after intravenous administration in pregnant and lactating mice.
    Ishii S, Mochizuki T, Nagao T, Kudo S, Fujita A, Taniguchi K, Kondo S, Kiyoki M.
    Arzneimittelforschung; 1995 May 01; 45(5):644-56. PubMed ID: 7612069
    [Abstract] [Full Text] [Related]

  • 20. Distribution of the recombinant coagulation factor 125I-rFVIIa in rats.
    Beeby TL, Chasseaud LF, Taylor T, Thomsen MK.
    Thromb Haemost; 1993 Sep 01; 70(3):465-8. PubMed ID: 8259550
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.